Immix Biopharma doses first patient in U.S. AL amyloidosis trial (NASDAQ:IMMX)

Immix Biopharma (NASDAQ:IMMX) on Monday announced that the first patient had been dosed in its U.S. NEXICART-2 trial with NXC-201.
The company added that the timing of the milestone was in-line with its mid-2024 guidance.
It also added that the data from its ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate.
Shares of IMMX dropped 7.20% to $2.19 during market hours.
Press release.

More on Immix Biopharma, Inc.

Previous Post: AI hardware stocks outpace market as infrastructure spending hits high gear

Next Post: Bitcoin (BTC) to Skyrocket 220%, According to ‘Bullish Megaphone’ Pattern By U.Today